further, by teaming up with other pharmaceutical companies, academic colleagues, and government agencies in partnerships such as TransCelerate BioPharma, the Critical Path Institute, and the Innovative Medicines Initiative in Europe, Lilly is helping to create much-needed industrywide standards of practice for things like riskbased monitoring, clinical site training, data standardization, and other efforts that will simplify the drug development process.